ProShares Ultra Health Care (RXL) Tin tức Mới Nhất, Cập Nhật Thị Trường & Tâm Lý | Edgen
Quay lại
Trang chủ
Cổ phiếu
RXL
ProShares Ultra Health Care (RXL)
Biểu đồ giá cổ phiếu RXL
RXL
ProShares Ultra Health Care
$56.59
-1.27%
$-0.72
Khi đóng cửa: Sep 10, 16:00:00 GMT-4
$56.59
0%
$0
Phiên sau giờ: Sep 10, 20:00:00 GMT-4
Tổng quan
Dự báo
Tài sản
Tin tức
Điều khoản
Thống kê chính
Giá đóng cửa trước
$57.32
Giá mở cửa
$56.96
Phạm vi ngày
$56.55 - $57.47
Phạm vi 52 tuần
$39.32 - $64.59
Khối lượng
6.0K
Khối lượng trung bình
11.1K
Tỷ suất cổ tức
1.55%
Tài sản ròng
$0
NAV
--
Tỷ lệ chi phí
--
Cổ phiếu đang lưu hành
1.5M
RXL là gì?
RXL was created on 2007-01-30 by ProShares. The fund's investment portfolio concentrates primarily on health care equity. RXL provides 2x leveraged exposure to a cap-weighted index of US health care companies.
Đặc điểm
Trợ lý AI cho Chứng khoán và Tiền mã hóa
Dự đoán giá cả
Tracker Huy động vốn
So sánh tiền điện tử
Trang chủ
Markets
US Stocks
HK Stocks
Crypto
News
Analyst Moves
Market Moves
Hong Kong IPO
Earnings
AI & Technology
Macro & Policy
Điều khoản sử dụng
Chính sách bảo mật
Sitemap
© 2026 Edgen được cấp phép bởi
Merck lifts pipeline target to $70B as KEYTRUDA cliff nears
Sep 10 2026, 10:37
Amgen falls 10% as Novartis Lp(a) trial failure clouds drug class
Sep 08 2026, 17:27
Moderna-Merck vaccine clears Phase 3, stock jumps 177% on melanoma data
Sep 06 2026, 18:55
Viking Therapeutics trades below targets as VK2735 oral safety questioned
Sep 06 2026, 00:57
Gilead's third FDA approval in 4 months lifts turnaround case
Sep 05 2026, 16:28
AbbVie closes $10.9B Apogee deal to expand immunology pipeline
Sep 03 2026, 13:01
Ivonescimab beats Keytruda on survival in 4th phase 3 win
Sep 02 2026, 22:28
Moderna stock doubles in August after melanoma trial win with Merck
Sep 01 2026, 11:27
Lilly Taltz-Zepbound combo sustains 30.6% skin-clearance goal at 52 weeks
Aug 31 2026, 14:34
Eli Lilly to buy Merida Biosciences for up to $2.875 billion
Aug 31 2026, 14:14
Amgen's Repatha cuts death risk 20% in high-risk primary prevention trial
Aug 31 2026, 12:24
Moderna stock surges 127% as cancer vaccine reshapes biotech outlook
Aug 30 2026, 17:52
Eli Lilly GLP-1 sales surge 48% as employer coverage falls to 60%
Aug 28 2026, 20:22
FDA approves Lilly's Mounjaro to cut cardiovascular risk 8%
Aug 28 2026, 12:35
Gilead's Bixlenvo wins FDA approval as first single-tablet HIV option
Aug 27 2026, 22:26
Pfizer, BioNTech win FDA approval for XFG COVID vaccine, 5B doses
Aug 27 2026, 20:54
FDA clears Roche, Eli Lilly Alzheimer's blood test for 55-plus patients
Aug 27 2026, 15:55
Tezspire meets EoE trial goals, expanding to 470,000 US patient pool
Aug 27 2026, 10:27